Stereotaxis Inc (STXS) 1.26 $STXS
Stereotaxis to Share its Latest Technology Advancements and Clinical Evidence at Cardiostim 2016 in Nice, France June 8-11
GlobeNewswire - Tue Jun 07, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will share the latest innovations to its Niobe ES magnetic navigation system and supporting clinical evidence at Cardiostim-EHRA Europace 2016, the 20th world congress in cardiac electrophysiology (EP) and cardiac techniques, taking place June 8-11 in Nice, France. The congress brings together more than 5,600 industry practitioners from over 125 countries to discuss the evolution of technologies and research advancements in the treatment of rhythm disorders.
STXS: 1.26 (+0.25)
Paracelsus Medical University Clinical Study on Stereotaxis Technology Benefits Recognized at European Cardiac Arrhythmia Society Congress
GlobeNewswire - Wed Jun 01, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of a retrospective study conducted at Paracelsus Medical University in Nuremberg, Germany, which showed significantly reduced radiation exposure for patients undergoing catheter ablation for persistent atrial fibrillation (AF) with the Niobe magnetic navigation system. The study received first place honors for "Best Poster Presentation" at the European Cardiac Arrhythmia Society Congress in Paris.
STXS: 1.26 (+0.25)
Stereotaxis Reports 2016 First Quarter Financial Results
GlobeNewswire - Mon May 09, 3:05PM CDT
-- Ventricular tachycardia procedures increased 27% year over year, representing the third consecutive quarter of 20%+ volume growth
STXS: 1.26 (+0.25)
Stereotaxis to Highlight New Clinical Results and Automation Enhancements at Heart Rhythm 2016 in San Francisco May 4-7
GlobeNewswire - Wed May 04, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the 37 Annual Heart Rhythm Society (HRS) Scientific Sessions, May 4-7, 2016 in San Francisco. During its 12 consecutive appearance at HRS, the Company will share results of recently published clinical studies, new technology enhancements, user experiences, and simulations of its computer-controlled mapping and lesion formation capabilities at Booth #1631.
STXS: 1.26 (+0.25)
Stereotaxis to Report First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Mon May 02, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2016 first quarter ended March 31, 2016 on Monday, May 9, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company's results and corporate developments.
STXS: 1.26 (+0.25)
Stereotaxis Awarded U.S. Patent for Vmotion Spotlight Automation Feature of Vdrive(R) Robotic Navigation System
GlobeNewswire - Fri Apr 29, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,314,222 titled, "Operation of a Remote Medical Navigation System Using Ultrasound Image." The patent protects the current Spotlight feature of the Company's Vmotion suite of automations, which enables automatic orientation of a magnetically compatible Intracardiac Echocardiography (ICE), or ultrasound, catheter to track a localized ablation catheter in conjunction with the Vdrive system with V-Sono ICE catheter manipulator.
STXS: 1.26 (+0.25)
Lund University Hospital Study Validates Improved Long-Term Clinical Outcomes Using Stereotaxis Technology
GlobeNewswire - Thu Apr 07, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of a long-term follow-up study on the efficacy of the Stereotaxis Niobe ES magnetic navigation system reported by Lund University Hospital in Sweden, which validate improved long-term clinical outcomes compared to manual navigation for ablation treatment of atrial fibrillation (AF). The study, presented as a scientific abstract at the American College of Cardiology Scientific Sessions April 2-4, represents the first published long-term clinical outcome results achieved purely with the latest generation Niobe system in AF ablation.
STXS: 1.26 (+0.25)
Change in Short Position and an Important Interview; Stereotaxis, Inc. (NASDAQ: STXS)
ACCESSWIRE - Mon Apr 04, 3:53PM CDT
ST. LOUIS, MO / ACCESSWIRE / April 4, 2016 / Stereotaxis, Inc. (NASDAQ: STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the Hoffman Heart and Vascular Institute at Saint Francis Hospital and Medical Center in Hartford, CT has started getting a lot of attention. We see some interesting information about the short position in this security and a very informative interview all shareholders should see.
STXS: 1.26 (+0.25)
U.S. Hospital Surpasses 1,000 Procedures using Stereotaxis Niobe(R) System
GlobeNewswire - Mon Apr 04, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the Hoffman Heart and Vascular Institute at Saint Francis Hospital and Medical Center in Hartford, CT has completed more than 1,000 cardiac ablation procedures using its Niobe remote magnetic navigation system. Drs. Joseph Dell'Orfano and Aneesh Tolat, electrophysiologists with Arrhythmia Consultants of Connecticut, were among the early adopters of the Niobe system and each has surpassed 500 procedures on the system, making the hospital the leading site in New England to use Stereotaxis technology.
STXS: 1.26 (+0.25)
Centre Hospitalier Regional Universitaire de Nancy Strengthens Leadership in Cardiac Rhythm Management through Stereotaxis Technology
GlobeNewswire - Fri Mar 18, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the first patients treated with the Niobe ES remote magnetic navigation system at the Centre Hospitalier Regional Universitaire de Nancy (CHRU of Nancy) in France. CHRU of Nancy is recognized as a pioneer of electrophysiology (EP) ablations in France, performing more than 900 procedures annually, and represents the fourth institution in the country to implement the Niobe system.
STXS: 1.26 (+0.25)
Journal of Cardiovascular Electrophysiology Publishes Special Issue Dedicated to Stereotaxis Technology
GlobeNewswire - Fri Mar 11, 8:00AM CST
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the Journal of Cardiovascular Electrophysiology (http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1540-8167), a publication of Wiley Periodicals and a leading peer-reviewed journal devoted to the study of electrophysiology (EP) of the heart, has published a special supplemental issue dedicated to Stereotaxis technology. The supplement is the first in the literature to focus solely on the Company's Niobe remote magnetic navigation system and features seven peer-reviewed clinical papers by more than 50 authors studying the results of the Niobe system in catheter ablation of complex arrhythmias.
STXS: 1.26 (+0.25)
University Medical Center New Orleans Implements Stereotaxis Platform for Advanced Treatment of Cardiac Arrhythmias
GlobeNewswire - Mon Feb 01, 8:09AM CST
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, and University Medical Center (UMC) New Orleans, the academic medical center of LCMC Health, today announced the first procedures performed using the Stereotaxis suite of products for electrophysiology (EP) ablation at UMC. The platform includes the Niobe ES remote magnetic navigation system, the Vdriverobotic navigation system and Odyssey information management solutions for lab optimization.
STXS: 1.26 (+0.25)
Stereotaxis Initiates Multi-Center Randomized Superiority Study on Ventricular Tachycardia Ablation Outcomes
GlobeNewswire - Mon Jan 11, 8:00AM CST
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it has initiated its first prospective, multi-center, randomized clinical study to compare radiofrequency ablation outcomes generated using its Niobe ES remote magnetic navigation system to manual approaches in ischemic scar ventricular tachycardia (VT) patients. VT is a rapid heart rhythm that, if left untreated, may lead to ventricular fibrillation and sudden cardiac death. It is estimated that approximately 60,000 ablations are performed annually on a worldwide basis to treat VT, with that number increasing by over 10% each year. In 2015, approximately 2,300 of these 60,000 procedures were performed using the Niobe system.
STXS: 1.26 (+0.25)
Multicenter Study Reveals Improved Long-Term Success Rates With Stereotaxis Technology in Ventricular Tachycardia
GlobeNewswire - Tue Nov 17, 8:00AM CST
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of an independent multicenter study on the procedural benefits and outcomes of patients undergoing radiofrequency ablation therapy for ventricular tachycardia (VT) using the Niobe remote magnetic navigation system compared to manual catheter approaches. The study findings, which were recently published at the American Heart Association Scientific Sessions, represent the most significant long-term outcomes to date with the Niobe system in VT and were considerably better than those in the manual catheter group.
STXS: 1.26 (+0.25)
Stereotaxis Reports 2015 Third Quarter Financial Results
GlobeNewswire - Tue Nov 03, 3:05PM CST
-Total Quarterly Revenue Increased 5% Year over Year on Improved System and Recurring Revenues-
STXS: 1.26 (+0.25)
Stereotaxis to Report Third Quarter 2015 Financial Results on November 3, 2015
GlobeNewswire - Tue Oct 27, 3:07PM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2015 third quarter ended September 30, 2015 on Tuesday, November 3, 2015 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company's results and corporate developments.
STXS: 1.26 (+0.25)
Stereotaxis Introduces Respiratory Compensation Feature for Remote Magnetic Navigation Procedures
GlobeNewswire - Mon Oct 12, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the worldwide launch of Respiratory Compensation, a new software feature of the Company's Niobe remote magnetic navigation system. Respiratory Compensation is designed to further enhance the quality and accuracy of Ablation History and the automation features of the Niobe system by compensating for respiratory motion during an ablation procedure.
STXS: 1.26 (+0.25)
Stereotaxis Announces Results of Warrants Offering
GlobeNewswire - Thu Oct 08, 8:00AM CDT
Stereotaxis, Inc. ("Stereotaxis"
(NASDAQ:STXS) a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of its previously announced offering of subscription warrants to purchase shares of its common stock at a price of $1.10 per share. Pursuant to the warrants offering, subscription warrants to purchase approximately 0.3 million shares of common stock were exercised, resulting in gross proceeds to Stereotaxis of approximately $300,000.
STXS: 1.26 (+0.25)
Stereotaxis Extends Warrants Offering Subscription Period
GlobeNewswire - Mon Sep 28, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced it is extending its registered offering of subscription warrants to the holders of common shares, as described in its prospectus supplement filed with the Securities and Exchange Commission (SEC) on September 4, 2015 (the "Prospectus" . The warrants offering was originally scheduled to expire on Wednesday, September 30, 2015 and the Company is extending the warrants offering by two days in order to better ensure that its stockholders who hold shares in brokerage accounts receive the offering materials and have time to act on them. The subscription warrants will now be exercisable until 5:00 p.m. New York City time on Friday, October 2, 2015.
STXS: 1.26 (+0.25)
Stereotaxis Launches Vmotion Suite of Automation Features in U.S. Following FDA Clearance
GlobeNewswire - Wed Sep 23, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the first procedures performed in the U.S. with its Vmotion suite of automation features. Cleared by the FDA this past June, Vmotion enables automatic orientation of a magnetically compatible Intracardiac Echocardiography (ICE) catheter in conjunction with the V-Sono(TM) ICE catheter manipulator.
STXS: 1.26 (+0.25)
Stereotaxis to Share its Latest Technology Advancements and Clinical Evidence at Cardiostim 2016 in Nice, France June 8-11
GlobeNewswire - Tue Jun 07, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will share the latest innovations to its Niobe ES magnetic navigation system and supporting clinical evidence at Cardiostim-EHRA Europace 2016, the 20th world congress in cardiac electrophysiology (EP) and cardiac techniques, taking place June 8-11 in Nice, France. The congress brings together more than 5,600 industry practitioners from over 125 countries to discuss the evolution of technologies and research advancements in the treatment of rhythm disorders.
STXS: 1.26 (+0.25)
Paracelsus Medical University Clinical Study on Stereotaxis Technology Benefits Recognized at European Cardiac Arrhythmia Society Congress
GlobeNewswire - Wed Jun 01, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of a retrospective study conducted at Paracelsus Medical University in Nuremberg, Germany, which showed significantly reduced radiation exposure for patients undergoing catheter ablation for persistent atrial fibrillation (AF) with the Niobe magnetic navigation system. The study received first place honors for "Best Poster Presentation" at the European Cardiac Arrhythmia Society Congress in Paris.
STXS: 1.26 (+0.25)
Stereotaxis Reports 2016 First Quarter Financial Results
GlobeNewswire - Mon May 09, 3:05PM CDT
-- Ventricular tachycardia procedures increased 27% year over year, representing the third consecutive quarter of 20%+ volume growth
STXS: 1.26 (+0.25)
Stereotaxis to Highlight New Clinical Results and Automation Enhancements at Heart Rhythm 2016 in San Francisco May 4-7
GlobeNewswire - Wed May 04, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the 37 Annual Heart Rhythm Society (HRS) Scientific Sessions, May 4-7, 2016 in San Francisco. During its 12 consecutive appearance at HRS, the Company will share results of recently published clinical studies, new technology enhancements, user experiences, and simulations of its computer-controlled mapping and lesion formation capabilities at Booth #1631.
STXS: 1.26 (+0.25)
Stereotaxis to Report First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Mon May 02, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2016 first quarter ended March 31, 2016 on Monday, May 9, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company's results and corporate developments.
STXS: 1.26 (+0.25)
Stereotaxis Awarded U.S. Patent for Vmotion Spotlight Automation Feature of Vdrive(R) Robotic Navigation System
GlobeNewswire - Fri Apr 29, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,314,222 titled, "Operation of a Remote Medical Navigation System Using Ultrasound Image." The patent protects the current Spotlight feature of the Company's Vmotion suite of automations, which enables automatic orientation of a magnetically compatible Intracardiac Echocardiography (ICE), or ultrasound, catheter to track a localized ablation catheter in conjunction with the Vdrive system with V-Sono ICE catheter manipulator.
STXS: 1.26 (+0.25)
Lund University Hospital Study Validates Improved Long-Term Clinical Outcomes Using Stereotaxis Technology
GlobeNewswire - Thu Apr 07, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of a long-term follow-up study on the efficacy of the Stereotaxis Niobe ES magnetic navigation system reported by Lund University Hospital in Sweden, which validate improved long-term clinical outcomes compared to manual navigation for ablation treatment of atrial fibrillation (AF). The study, presented as a scientific abstract at the American College of Cardiology Scientific Sessions April 2-4, represents the first published long-term clinical outcome results achieved purely with the latest generation Niobe system in AF ablation.
STXS: 1.26 (+0.25)
Change in Short Position and an Important Interview; Stereotaxis, Inc. (NASDAQ: STXS)
ACCESSWIRE - Mon Apr 04, 3:53PM CDT
ST. LOUIS, MO / ACCESSWIRE / April 4, 2016 / Stereotaxis, Inc. (NASDAQ: STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the Hoffman Heart and Vascular Institute at Saint Francis Hospital and Medical Center in Hartford, CT has started getting a lot of attention. We see some interesting information about the short position in this security and a very informative interview all shareholders should see.
STXS: 1.26 (+0.25)
U.S. Hospital Surpasses 1,000 Procedures using Stereotaxis Niobe(R) System
GlobeNewswire - Mon Apr 04, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the Hoffman Heart and Vascular Institute at Saint Francis Hospital and Medical Center in Hartford, CT has completed more than 1,000 cardiac ablation procedures using its Niobe remote magnetic navigation system. Drs. Joseph Dell'Orfano and Aneesh Tolat, electrophysiologists with Arrhythmia Consultants of Connecticut, were among the early adopters of the Niobe system and each has surpassed 500 procedures on the system, making the hospital the leading site in New England to use Stereotaxis technology.
STXS: 1.26 (+0.25)
Centre Hospitalier Regional Universitaire de Nancy Strengthens Leadership in Cardiac Rhythm Management through Stereotaxis Technology
GlobeNewswire - Fri Mar 18, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the first patients treated with the Niobe ES remote magnetic navigation system at the Centre Hospitalier Regional Universitaire de Nancy (CHRU of Nancy) in France. CHRU of Nancy is recognized as a pioneer of electrophysiology (EP) ablations in France, performing more than 900 procedures annually, and represents the fourth institution in the country to implement the Niobe system.
STXS: 1.26 (+0.25)
Journal of Cardiovascular Electrophysiology Publishes Special Issue Dedicated to Stereotaxis Technology
GlobeNewswire - Fri Mar 11, 8:00AM CST
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the Journal of Cardiovascular Electrophysiology (http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1540-8167), a publication of Wiley Periodicals and a leading peer-reviewed journal devoted to the study of electrophysiology (EP) of the heart, has published a special supplemental issue dedicated to Stereotaxis technology. The supplement is the first in the literature to focus solely on the Company's Niobe remote magnetic navigation system and features seven peer-reviewed clinical papers by more than 50 authors studying the results of the Niobe system in catheter ablation of complex arrhythmias.
STXS: 1.26 (+0.25)
University Medical Center New Orleans Implements Stereotaxis Platform for Advanced Treatment of Cardiac Arrhythmias
GlobeNewswire - Mon Feb 01, 8:09AM CST
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, and University Medical Center (UMC) New Orleans, the academic medical center of LCMC Health, today announced the first procedures performed using the Stereotaxis suite of products for electrophysiology (EP) ablation at UMC. The platform includes the Niobe ES remote magnetic navigation system, the Vdriverobotic navigation system and Odyssey information management solutions for lab optimization.
STXS: 1.26 (+0.25)
Stereotaxis Initiates Multi-Center Randomized Superiority Study on Ventricular Tachycardia Ablation Outcomes
GlobeNewswire - Mon Jan 11, 8:00AM CST
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it has initiated its first prospective, multi-center, randomized clinical study to compare radiofrequency ablation outcomes generated using its Niobe ES remote magnetic navigation system to manual approaches in ischemic scar ventricular tachycardia (VT) patients. VT is a rapid heart rhythm that, if left untreated, may lead to ventricular fibrillation and sudden cardiac death. It is estimated that approximately 60,000 ablations are performed annually on a worldwide basis to treat VT, with that number increasing by over 10% each year. In 2015, approximately 2,300 of these 60,000 procedures were performed using the Niobe system.
STXS: 1.26 (+0.25)
Multicenter Study Reveals Improved Long-Term Success Rates With Stereotaxis Technology in Ventricular Tachycardia
GlobeNewswire - Tue Nov 17, 8:00AM CST
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of an independent multicenter study on the procedural benefits and outcomes of patients undergoing radiofrequency ablation therapy for ventricular tachycardia (VT) using the Niobe remote magnetic navigation system compared to manual catheter approaches. The study findings, which were recently published at the American Heart Association Scientific Sessions, represent the most significant long-term outcomes to date with the Niobe system in VT and were considerably better than those in the manual catheter group.
STXS: 1.26 (+0.25)
Stereotaxis Reports 2015 Third Quarter Financial Results
GlobeNewswire - Tue Nov 03, 3:05PM CST
-Total Quarterly Revenue Increased 5% Year over Year on Improved System and Recurring Revenues-
STXS: 1.26 (+0.25)
Stereotaxis to Report Third Quarter 2015 Financial Results on November 3, 2015
GlobeNewswire - Tue Oct 27, 3:07PM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2015 third quarter ended September 30, 2015 on Tuesday, November 3, 2015 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company's results and corporate developments.
STXS: 1.26 (+0.25)
Stereotaxis Introduces Respiratory Compensation Feature for Remote Magnetic Navigation Procedures
GlobeNewswire - Mon Oct 12, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the worldwide launch of Respiratory Compensation, a new software feature of the Company's Niobe remote magnetic navigation system. Respiratory Compensation is designed to further enhance the quality and accuracy of Ablation History and the automation features of the Niobe system by compensating for respiratory motion during an ablation procedure.
STXS: 1.26 (+0.25)
Stereotaxis Announces Results of Warrants Offering
GlobeNewswire - Thu Oct 08, 8:00AM CDT
Stereotaxis, Inc. ("Stereotaxis"
(NASDAQ:STXS) a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of its previously announced offering of subscription warrants to purchase shares of its common stock at a price of $1.10 per share. Pursuant to the warrants offering, subscription warrants to purchase approximately 0.3 million shares of common stock were exercised, resulting in gross proceeds to Stereotaxis of approximately $300,000. STXS: 1.26 (+0.25)
Stereotaxis Extends Warrants Offering Subscription Period
GlobeNewswire - Mon Sep 28, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced it is extending its registered offering of subscription warrants to the holders of common shares, as described in its prospectus supplement filed with the Securities and Exchange Commission (SEC) on September 4, 2015 (the "Prospectus"
. The warrants offering was originally scheduled to expire on Wednesday, September 30, 2015 and the Company is extending the warrants offering by two days in order to better ensure that its stockholders who hold shares in brokerage accounts receive the offering materials and have time to act on them. The subscription warrants will now be exercisable until 5:00 p.m. New York City time on Friday, October 2, 2015. STXS: 1.26 (+0.25)
Stereotaxis Launches Vmotion Suite of Automation Features in U.S. Following FDA Clearance
GlobeNewswire - Wed Sep 23, 8:00AM CDT
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the first procedures performed in the U.S. with its Vmotion suite of automation features. Cleared by the FDA this past June, Vmotion enables automatic orientation of a magnetically compatible Intracardiac Echocardiography (ICE) catheter in conjunction with the V-Sono(TM) ICE catheter manipulator.
STXS: 1.26 (+0.25)
